

Figure 1. Aspirin for the prevention of cardiovascular disease: clinical summary of a U.S. Preventive Services Task Force recommendation statement.

Annals of Internal Medicine



ASPIRIN FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
CLINICAL SUMMARY OF U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATION

Population	Men Age 45–79 Years	Women Age 55–79 Years	Men Age <45 Years	Women Age <55 Years	Men and Women Age ≥80 Years																								
Recommendation	Encourage aspirin use when potential CVD benefit (MIs prevented) outweighs potential harm of GI hemorrhage	Encourage aspirin use when potential CVD benefit (strokes prevented) outweighs potential harm of GI hemorrhage	Do not encourage aspirin use for MI prevention	Do not encourage aspirin use for stroke prevention	No Recommendation																								
	Grade: A		Grade: D		Grade: I (insufficient evidence)																								
How to Use This Recommendation	<p>Shared decision making is strongly encouraged with individuals whose risk is close to (either above or below) the estimates of 10-year risk levels indicated below. As the potential CVD benefit increases above harms, the recommendation to take aspirin should become stronger.</p> <p>To determine whether the potential benefit of MIs prevented (men) and strokes prevented (women) outweighs the potential harm of increased GI hemorrhage, both 10-year CVD risk and age must be considered.</p> <table border="1"> <thead> <tr> <th colspan="4">Risk Level at Which CVD Events Prevented (Benefit) Exceeds GI Harms</th> </tr> <tr> <th colspan="2">Men</th> <th colspan="2">Women</th> </tr> <tr> <th>Age</th> <th>10-Year CHD Risk</th> <th>Age</th> <th>10-Year Stroke Risk</th> </tr> </thead> <tbody> <tr> <td>45–59 years</td> <td>≥4%</td> <td>55–59 years</td> <td>≥3%</td> </tr> <tr> <td>60–69 years</td> <td>≥9%</td> <td>60–69 years</td> <td>≥8%</td> </tr> <tr> <td>70–79 years</td> <td>≥12%</td> <td>70–79 years</td> <td>≥11%</td> </tr> </tbody> </table> <p>The table above applies to adults who are not taking NSAIDs and who do not have upper GI pain or a history of GI ulcers. NSAID use and history of GI ulcers increase the risk for serious GI bleeding events considerably and should be considered in determining the balance of benefits and harms.</p> <p>NSAID use combined with aspirin use approximately quadruples the risk for serious GI bleeding events compared with the risk with aspirin use alone. The rate of serious bleeding in aspirin users is approximately 2 to 3 times greater in patients with a history of GI ulcers.</p>					Risk Level at Which CVD Events Prevented (Benefit) Exceeds GI Harms				Men		Women		Age	10-Year CHD Risk	Age	10-Year Stroke Risk	45–59 years	≥4%	55–59 years	≥3%	60–69 years	≥9%	60–69 years	≥8%	70–79 years	≥12%	70–79 years	≥11%
Risk Level at Which CVD Events Prevented (Benefit) Exceeds GI Harms																													
Men		Women																											
Age	10-Year CHD Risk	Age	10-Year Stroke Risk																										
45–59 years	≥4%	55–59 years	≥3%																										
60–69 years	≥9%	60–69 years	≥8%																										
70–79 years	≥12%	70–79 years	≥11%																										
Risk Assessment	<p>For men: Risk factors for CHD include age, diabetes, total cholesterol level, HDL cholesterol level, blood pressure, and smoking. CHD risk estimation tool: http://healthlink.mcw.edu/article/923521437.html</p> <p>For women: Risk factors for ischemic stroke include age, high blood pressure, diabetes, smoking, history of CVD, atrial fibrillation, and left ventricular hypertrophy. Stroke risk estimation tool: www.westernstroke.org/PersonalStrokeRisk1.xls</p>																												
Relevant Recommendations from the USPSTF	<p>The USPSTF has made recommendations on screening for abdominal aortic aneurysm, carotid artery stenosis, CHD, high blood pressure, lipid disorders, and peripheral arterial disease. These recommendations are available at www.preventiveservices.ahrq.gov.</p>																												

For the full recommendation statement and supporting documents, please go to www.preventiveservices.ahrq.gov.

CHD = coronary heart disease; CVD = cardiovascular disease; GI = gastrointestinal; HDL = high-density lipoprotein; MI = myocardial infarction; NSAID = nonsteroidal anti-inflammatory drug; USPSTF = U.S. Preventive Services Task Force.

Table 1. What the USPSTF Grades Mean and Suggestions for Practice

Grade	Definition	Suggestions for Practice
A	The USPSTF recommends the service. There is high certainty that the net benefit is substantial.	Offer/provide this service.
B	The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.	Offer/provide this service.
C	The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is moderate or high certainty that the net benefit is small.	Offer/provide this service only if other considerations support offering or providing the service in an individual patient.
D	The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.	Discourage the use of this service.
I statement	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.	Read the clinical considerations section of the USPSTF Recommendation Statement. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.

USPSTF = U.S. Preventive Services Task Force.

Table 2. U.S. Preventive Services Task Force Levels of Certainty Regarding Net Benefit

Level of Certainty*	Description
High	The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.
Moderate	The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as: the number, size, or quality of individual studies inconsistency of findings across individual studies limited generalizability of findings to routine primary care practice lack of coherence in the chain of evidence. As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.
Low	The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of: the limited number or size of studies important flaws in study design or methods inconsistency of findings across individual studies gaps in the chain of evidence findings that are not generalizable to routine primary care practice a lack of information on important health outcomes. More information may allow an estimation of effects on health outcomes.

* The U.S. Preventive Services Task Force (USPSTF) defines *certainty* as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as benefit minus harm of the preventive service as implemented in a general primary care population. The USPSTF assigns a certainty level based on the nature of the overall evidence available to assess the net benefit of a preventive service.